178 related articles for article (PubMed ID: 10210515)
1. Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist.
Thibault B; Nattel S
J Cardiovasc Electrophysiol; 1999 Mar; 10(3):472-81. PubMed ID: 10210515
[TBL] [Abstract][Full Text] [Related]
2. [Antiarrhythmic therapy in patients with heart failure].
Faber TS; Zehender M
Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
[TBL] [Abstract][Full Text] [Related]
3. Antiarrhythmic drug initiation in patients with atrial fibrillation.
Pinski SL; Helguera ME
Prog Cardiovasc Dis; 1999; 42(1):75-90. PubMed ID: 10505494
[TBL] [Abstract][Full Text] [Related]
4. [The pro-arrhythmic effects of anti-arrhythmia agents].
Haverkamp W; Wichter T; Chen X; Hördt M; Willems S; Rotman B; Hindricks G; Kottkamp H; Borggrefe M; Breithardt G
Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949
[TBL] [Abstract][Full Text] [Related]
5. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Lazzara R
Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
[TBL] [Abstract][Full Text] [Related]
6. A benefit-risk assessment of class III antiarrhythmic agents.
Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
[TBL] [Abstract][Full Text] [Related]
7. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
Hohnloser SH
Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
[TBL] [Abstract][Full Text] [Related]
8. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
[TBL] [Abstract][Full Text] [Related]
9. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
Borggrefe M; Haverkamp W; Shenasa M; Hindricks G; Breithardt G
J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S32-40. PubMed ID: 1279307
[TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
Singh BN; Wadhani N
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
[TBL] [Abstract][Full Text] [Related]
11. Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues.
Reiffel JA
Curr Opin Cardiol; 2000 Jan; 15(1):7-11. PubMed ID: 10666656
[TBL] [Abstract][Full Text] [Related]
12. Clinical types of proarrhythmic response to antiarrhythmic drugs.
Bigger JT; Sahar DI
Am J Cardiol; 1987 Apr; 59(11):2E-9E. PubMed ID: 3554950
[TBL] [Abstract][Full Text] [Related]
13. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
Steinbeck G
Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
[TBL] [Abstract][Full Text] [Related]
14. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
Hohnloser SH; Singh BN
J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113
[TBL] [Abstract][Full Text] [Related]
15. Effects of antiarrhythmic drugs on QT interval dispersion--relationship to antiarrhythmic action and proarrhythmia.
Gillis AM
Prog Cardiovasc Dis; 2000; 42(5):385-96. PubMed ID: 10768315
[TBL] [Abstract][Full Text] [Related]
16. Evolving role of sotalol in the management of ventricular tachyarrhythmias.
O'Callaghan PA; McGovern BA
Am J Cardiol; 1996 Aug; 78(4A):54-60. PubMed ID: 8780329
[TBL] [Abstract][Full Text] [Related]
17. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
[TBL] [Abstract][Full Text] [Related]
18. Amiodarone and torsades de pointes in patients with advanced heart failure.
Middlekauff HR; Stevenson WG; Saxon LA; Stevenson LW
Am J Cardiol; 1995 Sep; 76(7):499-502. PubMed ID: 7653452
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics and management of proarrhythmias during antiarrhythmic therapy].
Kobayashi Y
Nihon Rinsho; 2013 Jan; 71(1):79-85. PubMed ID: 23631176
[TBL] [Abstract][Full Text] [Related]
20. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
Singh BN
J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
